Recently infected patients show immune benefit when interleukin-2 is added to antirectroviral therap
In an early report from an ongoing, randomized clinical trial, researchers from UCSF have shown that the addition of the immune stimulator interleukin-2 (IL-2) to highly active antiretroviral therapy (HAART) improves immune function in patients who have been recently infected with HIV.